Industries
Epigenomics and Chromatin Biology
Epigenomics companies target chromatin-modifying enzymes—HATs, HDACs, methyltransferases—to reverse aberrant gene silencing in cancer and immune disorders. University chromatin biology labs are key IP sources for novel histone modification pathways, screening assays, and epigenetic biomarkers that companies incorporate into drug discovery programs.
Details
- Companies
- Constellation Pharmaceuticals MorphoSysEpiZyme SyndaxKymera TherapeuticsC4 TherapeuticsImago BioSciencesPrelude TherapeuticsActive MotifEpigenomIQCellectar BiosciencesCelldex Therapeutics
- Market Size
- $3.9B
- Target Researchers
- Epigenomicists and chromatin biologists specializing in histone modification, DNA methylation, ATAC-seq, ChIP-seq, CUT and RUN, chromatin remodeling complexes, and small-molecule modulation of epigenetic writers, readers, and erasers
- Use Cases
- HDAC and DNMT inhibitor co-developmentEpigenomic profiling CRO servicesChromatin remodeler target licensingDegrader PROTAC epigenetic target accessPrecision oncology biomarker developmentChIP-seq and ATAC-seq data analysis partnerships